| [1] |
Bahn RS. Graves′ ophthalmopathy[J]. N Engl J Med, 2010, 362(8): 726-738.
|
| [2] |
宋国祥. 眼眶病学[M]. 北京：人民卫生出版社，2010.
|
| [3] |
Maheshwari R, Weis E. Thyroid associated orbitopathy[J]. Indian J Ophthalmol, 2012, 60(2): 87-93.
|
| [4] |
Kashkouli MB, Alemzadeh SA, Aghaei H, et al. Subjective vs objective dry eye disease in patients with moderate-severe thyroid eye disease[J]. Ocul Surf, 2018, 16(4): 458-462.
|
| [5] |
Achtsidis V, Tentolouris N, Theodoropoulou S, et al. Dry eye in Graves′ ophthalmopathy: correlation with corneal hypoesthesia[J]. Eur J Ophthalmol, 2013, 23(4): 473-479.
|
| [6] |
Selter JH, Gire AI, Sikder S. The relationship between Graves′ ophthalmopathy and dry eye syndrome[J]. Clin Ophthalmol, 2015, 9: 57-62.
|
| [7] |
Iskeleli G, Karakoc Y, Abdula A. Tear film osmolarity in patients with thyroid ophthalmopathy[J]. Jpn J Ophthalmol, 2008, 52(4): 323-326.
|
| [8] |
Bruscolini A, Abbouda A, Locuratolo N, et al. Dry eye syndrome in non-exophthalmic Graves′ disease[J]. Semin Ophthalmol, 2015, 30(5/6): 372-376.
|
| [9] |
Aggarwal S, Galor A. What′s new in dry eye disease diagnosis? [J]. F1000Research, 2018, 7: 1952.
|
| [10] |
Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome[J]. Nat Rev Disease primers, 2016, 2(15): 16047.
|
| [11] |
Rosenbaum JT, Choi D, Harrington CA, et al. Gene expression profiling and heterogeneity of nonspecific orbital inflammation affecting the lacrimal gland[J]. JAMA Ophthalmol, 2017, 135(11): 1156-1162.
|
| [12] |
Łacheta D, Miskiewicz P, Głuszko A, et al. Immunological aspects of Graves′ ophthalmopathy[J]. Biomed Res Int, 2019, 2019：7453260.
|
| [13] |
Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor[J]. J Clin Endocrinol Metab, 2004, 89(10): 5076-5080.
|
| [14] |
Marinò M, Rotondo DG, Ionni I, et al. Serum antibodies against the insulin-like growth factor-1 receptor in Graves′ disease and Graves′ orbitopathy[J]. J Endocrinol Invest, 2019, 42(4): 471-480.
|
| [15] |
Gerding MN, van Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves′ ophthalmopathy[J]. Clin Endocrinol, 2000, 52(3): 267-271.
|
| [16] |
Harris MA, Realini T, Hogg JP, et al. CT dimensions of the lacrimal gland in Graves orbitopathy[J]. Ophthal Plast Reconstr Surg, 2012, 28(1): 69-72.
|
| [17] |
王毅，孙丰源. 细胞间黏附分子-1在甲状腺相关眼病泪腺组织中的表达及意义[J]. 眼科研究，2003, 21 (2): 153-155.
|
| [18] |
Park J, Baek S. Dry eye syndrome in thyroid eye disease patients: The role of increased incomplete blinking and Meibomian gland loss[J]. Acta Ophthalmol, 2019, 97(5): e800-e806.
|
| [19] |
Rocha EM, Mantelli F, Nominato LF, et al. Hormones and dry eye syndrome: an update on what we do and don′t know[J]. Curr Opin Ophthalmol, 2013, 24(4): 348-355.
|
| [20] |
Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome[J]. J Proteomics, 2012, 75(13): 3877-3885.
|
| [21] |
De Souza GA, De Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors[J]. Genome Biol, 2006, 7(8): R72.
|
| [22] |
程妍. 甲状腺相关眼病患者血清及泪液TPOAb、TRAb的检测及相关性分析[D]. 长春：吉林大学，2014.
|
| [23] |
Aass C, Norheim I, Eriksen EF, et al. Comparative proteomic analysis of tear fluid in Graves′ disease with and without orbitopathy[J]. Clin Endocrinol (Oxf), 2016, 85(5): 805-812.
|
| [24] |
Huang D, Luo Q, Yang H, et al. Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy[J]. Invest Ophthalmol Vis Sci, 2014, 55(8): 4935-4943.
|
| [25] |
Khalil HA, De Keizer RJW, Bodelier VMW, et al. Secretory IgA and lysozyme in tears of patients with Graves′ ophthalmopathy[J]. Doc Ophthalmol, 1989, 72(3): 329-334.
|
| [26] |
Khalil HA, Keizer RJW, Kijlstra A. Analysis of tear proteins in Graves′ ophthalmopathy by high performance liquid chromatography[J]. Am J Ophthalmol, 1988, 106(2): 186-190.
|
| [27] |
Baker GR, Morton M, Rajapaska RS, et al. Altered tear composition in smokers and patients with graves ophthalmopathy[J]. Arch Ophthalmol, 2006, 124(10): 1451-1456.
|
| [28] |
Aass C, Norheim I, Eriksen EF, et al. Establishment of a tear protein biomarker panel differentiating between Graves′ disease with or without orbitopathy[J]. PLoS One, 2017, 12(4): e0175274.
|
| [29] |
Chng CL, Seah LL, Yang M, et al. Tear proteins calcium binding protein A4 and prolactin induced protein are potential biomarkers for thyroid eye disease[J]. Sci Rep, 2018, 8(1): 16936.
|
| [30] |
Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy[J]. Sci Rep, 2018, 8(1): 10792.
|
| [31] |
Huang D, Xu N, Song Y, et al. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy[J]. Graefe′s Arch Clin Exp Ophthalmol, 2012, 250(4): 619-25.
|
| [32] |
Sadoul JL. L′ophtalmopathie thyroïdienne à l'heure de l′European Group on Graves orbitopathy [J]. Presse Med, 2011, 40(12): 1163-1173.
|
| [33] |
Bartalena L, Pinchera A, Marcocci C. Management of Graves′ ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2000, 21(2): 168-199.
|
| [34] |
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves′ Orbitopathy guidelines for the Management of Graves′ Orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.
|
| [35] |
Mourits MPH, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves′ ophthalmopathy: a novel approach[J]. Br J Ophthalmol, 1989, 73(8): 639-644.
|
| [36] |
Ferreira TA, Saraiva P, Genders SW, et al. CT and MR imaging of orbital inflammation[J]. Neuroradiology, 2018, 60(12): 1253-1266.
|
| [37] |
Byun JS, Moon NJ, Lee JK. Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy[J]. Graefe′s Arch Clin Exp Ophthalmol, 2017, 255(2): 413-420.
|
| [38] |
Regensburg NI, Kok PH, Zonneveld FW, et al. A new and validated CT-based method for the calculation of orbital soft tissue volumes[J]. Invest Ophthalmol Vis Sci, 2008, 49(5): 1758-1762.
|
| [39] |
Huh HD, Kim JH, Kim SJ, et al. The change of lacrimal gland volume in Korean patients with thyroid-associated ophthalmopathy[J]. Korean J Ophthalmol, 2016, 30(5): 319-325.
|
| [40] |
Conneely MF, Hacein-Bey L, Jay WM. Magnetic resonance imaging of the orbit[J]. Semin Ophthalmol, 2008, 23(3): 179-189.
|
| [41] |
Kahaly GJ. Recent developments in Graves′ ophthalmopathy imaging[J]. J Endocrinol Invest, 2004, 27(3): 254-258.
|
| [42] |
韩雪立，吴恩余. Graves眼病的CT和MRI影像学分析[J]. 白求恩医科大学学报，2001, 17(5): 540-542.
|
| [43] |
Hu H, Xu XQ, Wu FY, et al. Diagnosis and stage of Graves′ ophthalmopathy: Efficacy of quantitative measurements of the lacrimal gland based on 3-T magnetic resonance imaging[J]. Exp Ther Med, 2016, 12(2): 725-729.
|
| [44] |
Gagliardo C, Radellini S, Bubella RM, et al. Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity[J]. Eur Radiol, 2020, 30(1): 2138-2141.
|
| [45] |
沈洁，戈荧，范艳飞，等. 泪腺及眼外肌MRI-T2值在甲状腺相关眼病活动期评判中的价值[C]. 杭州：中华医学会第十次全国内分泌学学术会议，2011.
|
| [46] |
Krassas GE. Somatostatin analogues in the treatment of thyroid eye disease[J]. Thyroid, 1998, 8(5): 443-445.
|
| [47] |
孙斌. 生长抑素类似物眼眶显像在甲状腺相关性眼病诊疗中的应用[J]. 眼科，2016, 25(6): 361-364.
|
| [48] |
孙斌，吕兆琴，李险峰. 甲状腺相关眼病眶部99Tcm-生长抑素类似物受体显像的应用价值[J]. 中国实用眼科杂志，2008, 26(1): 90-92.
|
| [49] |
Moncayo R, Baldissera I, Decristoforo C, et al. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide[J]. Thyroid, 1997, 7(1): 21-29.
|
| [50] |
Sweeney RA, Bale RJ, Moncayo R, et al. Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report[J]. Strahlenther Onkol, 2003, 179(4): 254-260.
|
| [51] |
孙斌，姚国敏，段春青，等. 甲状腺相关性眼病眶部99Tcm-生长抑素类似物受体显像与CAS评分的相关性研究[J]. 中国实用眼科杂志，2008, 26(12): 1305-1308.
|
| [52] |
Decristoforo C, Mather SJ, Cholewinski W, et al. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives[J]. Eur J Nucl Med, 2000, 27(9): 1318-1325.
|
| [53] |
杨宝军，李险峰，陆克义，等. 99mTc-DTPA眼眶显像在甲状腺相关性眼病中的临床应用[J]. 山西医科大学学报，2009, 40(6): 563-566.
|
| [54] |
蒋承志，李新辉，赵敏，等. 99mTc-DTPA眼眶SPECT/CT对甲状腺相关性眼病泪腺炎症的评估价值[J]. 中南大学学报(医学版), 2019, 44(3): 322-328.
|